Aslan Pharmaceuticals Ltd ADR (ASLN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2022 | 09-2022 | 06-2022 | 03-2022 | 12-2021 | |
| Operating Expenses | 13,394 | 10,295 | 12,301 | 11,894 | 4,271 |
| Operating Income | -13,394 | -10,295 | -12,301 | -11,894 | -4,271 |
| Interest Expense | 778 | 937 | 877 | 1,083 | 336 |
| Other Income | -230 | 322 | 143 | 40 | 960 |
| Pre-tax Income | -14,402 | -10,910 | -13,035 | -12,937 | -3,647 |
| Income Tax | 79 | 20 | N/A | N/A | N/A |
| Net Income Continuous | -14,481 | -10,930 | -13,035 | -12,937 | -3,647 |
| Net Income | $-14,481 | $-10,930 | $-13,035 | $-12,937 | $-3,647 |
| EPS Basic Total Ops | -8.32 | -6.24 | -7.44 | -7.44 | -1.20 |
| EPS Basic Continuous Ops | -8.31 | -6.27 | -7.48 | -7.42 | -0.87 |
| EPS Diluted Total Ops | -8.32 | -6.24 | -7.44 | -7.44 | -1.20 |
| EPS Diluted Continuous Ops | -8.31 | -6.27 | -7.48 | -7.42 | -0.87 |
| EPS Diluted Before Non-Recurring Items | -8.32 | -6.40 | -7.60 | N/A | N/A |
| EBITDA(a) | $-13,394 | $-10,295 | $-12,301 | $-11,894 | $-4,271 |